ONCO-INNOVATIONS LTD (ONNVF)
ONNVF moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How ONNVF actually reacts to news — the realized, point-in-time move the market made, measured across 79 labeled events over the last three years with zero look-ahead.
ONNVF’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 0% | 19 |
| 30-min | 0.00% | 5% | 19 |
| 60-min | 0.00% | 11% | 19 |
| to close | 0.00% | 21% | 19 |
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ONNVF moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ONNVF's baseline. Nothing else.
Recent ONNVF events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Onco-Innovations and Redwood AI Secure Terry Fox Research Institute Grant to Advance AI-Powered SynoGraph(TM) Oncology Platform | Press release | ACCESS Newswire | +0.00% | +0.00% | |
| IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Islam Mohamed, Chief Medical Officer of Onco-Innovations Ltd. | Press release | GlobeNewswire | — | — | |
| Onco-Innovations Enters into LOI with Ifowonco for Exclusive Option and Worldwide Licence to LAG-3 Small-Molecule Inhibitor Program | Press release | ACCESS Newswire | — | — | |
| Onco-Innovations Completes Analytical Reference Standard Preparation Program for ONC010’s API | Press release | ACCESS Newswire | +0.00% | -5.61% | |
| Onco-Innovations Announces Term Sheet for Notional CAD$5 Million Performance-Based Funding Arrangement and Amendments to Previously Announced Financing | Press release | ACCESS Newswire | +0.00% | +0.00% | |
| Onco-Innovations Initiates Polymer Process Development and Characterization Program for ONC010 | Press release | ACCESS Newswire | +0.00% | +0.00% | |
| NetworkNewsAudio Announces Audio Press Release (APR) Discussing the Development of PNKP Inhibitors in Oncology Drug Development | Press release | GlobeNewswire | +0.00% | +7.36% | |
| Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010 | Press release | ACCESS Newswire | +0.00% | -0.19% | |
| Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Leading Out in Developing Fresh Wave of Inhibitor Classes | Press release | GlobeNewswire | +0.00% | -6.09% | |
| Onco-Innovations Engages Nanosoft Polymers to Advance Polymer and Drug Delivery Development for ONC010 | Press release | ACCESS Newswire | +0.00% | +7.55% | |
| Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Advancing Nanoparticle-Encapsulated PNKP Inhibitor in Oncology Space | Press release | GlobeNewswire | +0.00% | +3.05% | |
| Onco-Innovations Announces Non-Brokered LIFE Offering | Press release | ACCESS Newswire | +0.00% | +0.00% | |
| Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development | Press release | ACCESS Newswire | +0.00% | +0.00% | |
| Onco-Innovations Completes Project with Kuano, Using Their Quantum-Based Platform to Deliver Insights for PNKP Inhibitor Technology Optimization | Press release | ACCESS Newswire | — | — | |
| Onco-Innovations Announces Initiation of API Process Development and Intermediate Scale-Up Program for its Proprietary PNKP Inhibitor Technology | Press release | ACCESS Newswire | — | — | |
| Onco-Innovations Signs LOI with Nanosoft Polymers to Advance Polymer and Drug Delivery Development for the ONC010 Program | Press release | ACCESS Newswire | — | — | |
| Onco-Innovations Advances 1kg Scale-Up of B4 Precursor Supporting ONC010 Manufacturing and Clinical Development Program | Press release | ACCESS Newswire | — | — | |
| Onco-Innovations Reports Continued Advancement of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for ONC010 Development Program | Press release | ACCESS Newswire | +0.00% | +3.28% | |
| Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate | Press release | ACCESS Newswire | +0.00% | +0.00% | |
| Onco-Innovations Announces Initiation of Research Collaboration within PROmAI | Press release | ACCESS Newswire | — | — | |
| Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology | Press release | ACCESS Newswire | +0.00% | +0.00% | |
| Onco-Innovations Announces Inka Health Collaborative Research to Advance Oncology Evidence Generation | Press release | ACCESS Newswire | — | — | |
| Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies | Press release | ACCESS Newswire | — | — | |
| Onco-Innovations Announces Successful Scale-Up of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for its PNKP Inhibitor Technology Program | Press release | ACCESS Newswire | +0.00% | -2.43% | |
| Onco-Innovations Advances Polymer Testing as It Moves Its PNKP Inhibitor Technology Toward IND-Enabling Studies | Press release | ACCESS Newswire | +0.00% | -5.50% | |
| Onco-Innovations Announces Completion of Analytical Method Development for Monomer Intermediate 1 Supporting ONC010 Program | Press release | ACCESS Newswire | +0.00% | -5.11% | |
| Onco-Innovations Strengthens Executive Leadership with Appointment of Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development | Press release | ACCESS Newswire | +0.00% | +0.00% | |
| Onco-Innovations Executes Engagement Agreement with RDI Partners and Establishes Onco-Innovations AU Pty. Ltd. to Advance Australian Phase I Strategy | Press release | ACCESS Newswire | +0.00% | -6.49% | |
| Onco-Innovations Announces Closing of Private Placement | Press release | ACCESS Newswire | — | — | |
| Onco-Innovations Announces Amendment to Private Placement Pricing | Press release | ACCESS Newswire | — | — | |
| Onco-Innovations Announces Filing of Preliminary Base Shelf Prospectus | Press release | ACCESS Newswire | — | — | |
| Onco-Innovations Announces Private Placement | Press release | ACCESS Newswire | — | — | |
| Onco-Innovations Engages i2i Marketing Group Engagement for Market Awareness Services | Press release | ACCESS Newswire | — | — | |
| Onco-Innovations Chairs Colorectal Cancer Canada Precision Oncology Forum Generating Roadmaps for the Next Era of Cancer Care | Press release | ACCESS Newswire | — | — | |
| Onco-Innovations Engages Investment Bank to Pursue Nasdaq Cross-listing and Potential Concurrent Equity Offering | Press release | ACCESS Newswire | — | — | |
| Onco-Innovations Attends University of Alberta's 2025 Innovation Awards | Press release | ACCESS Newswire | — | — | |
| Onco-Innovations Advances Optimization and Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services to Support Future Phase 1 Clinical Studies | Press release | ACCESS Newswire | — | — | |
| Onco-Innovations Advances AI and Quantum Drug Discovery with Kuano Collaboration to Accelerate PNKP Inhibitor Technology Development | Press release | ACCESS Newswire | — | — | |
| Onco-Innovations' Inka Health Publishes Framework on Transportability of Real-World Evidence and Use in Health Technology Assessment | Press release | ACCESS Newswire | — | — | |
| Onco-Innovations Provides Shareholder Update Following Cboe Canada Investor Spotlight | Press release | ACCESS Newswire | — | — | |
| Onco-Innovations Appoints Jared Rushton to Board of Directors | Press release | ACCESS Newswire | — | — | |
| Onco-Innovations Announces Closing of Private Placement | Press release | ACCESS Newswire | — | — | |
| Onco-Innovations Announces Private Placement | Press release | ACCESS Newswire | — | — | |
| Onco-Innovations Advances Preclinical Program as Nucro-Technics Begins Analytical Development for PNKP Technology | Press release | ACCESS Newswire | — | — | |
| Onco-Innovations Appoints Dr. Michael Lock to Scientific & Clinical Advisory Board | Press release | ACCESS Newswire | — | — | |
| Onco-Innovations Commences Activities to Manufacture Nanoparticle Formulation with Dalton Pharma to Supply Preclinical Animal Studies | Press release | ACCESS Newswire | — | — | |
| Onco-Innovations to Chair Colorectal Cancer Canada Precision Oncology Forum Driving the Future of Cancer Care | Press release | ACCESS Newswire | — | — | |
| Onco-Innovations Appoints Dr. John Mackey to Scientific & Clinical Advisory Board | Press release | ACCESS Newswire | — | — | |
| Onco-Innovations Announces 90% of $0.60 Warrants Have Been Exercised | Press release | ACCESS Newswire | — | — | |
| Onco-Innovations Announces Closing of Private Placement | Press release | ACCESS Newswire | — | — |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ONNVF section they belong to.
Where else ONNVF is measured.
ONNVF earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is ONCO-INNOVATIONS LTD's median reaction calculated?
Every labeled ONNVF news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 79 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 5% of ONNVF's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ONNVF's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.